{"Clinical Trial ID": "NCT00291694", "Intervention": ["INTERVENTION 1:", "Celecoxib", "- randomized to receive celecoxib per day for 12 months", "INTERVENTION 2:", "- Placebo", "- randomised to receive placebo daily for 12 months"], "Eligibility": ["Incorporation criteria:", "Women at high risk of breast cancer", "\u2022 Over 18 years of age", "- Exclusion criteria:", "Anticoagulants", "- Marked breast sensitivity", "\u2022 Pregnant women or within 12 months of breastfeeding/birth"], "Results": ["Performance measures:", "Change in percentage of breast epithelial cells that are positive for Ki-67", "The immunocytochemical staining of the breast epithelial cells. Positive cells reflect the proliferative activity.", "Time frame: baseline and 12 months", "Results 1:", "Title of the arm/group: Celecoxib", "Description of the arm/group: randomized to receive celecoxib per day for 12 months", "Total number of participants analysed: 43", "Median (full range)", "Unit of measurement: percentage of positive cell stains -1,2 (-18 to 14.8)", "Results 2:", "Title of the arm/group: Placebo", "Description of the arm/group: randomized to receive placebo daily for 12 months", "Total number of participants analysed: 21", "Median (full range)", "Unit of measurement: percentage of positive cell stains -2.0 (-8.8-12.2)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/43 (0.00 per cent)", "Adverse Events 2:", "Grand total"]}